Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.

The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including acute myeloid leukemia ... which drives chronic ...

Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

Specific inflammatory cytokines can predict infection risk in leukemia in patients undergoing chemotherapy, according to a study in Microbial Pathogenesis.

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Indian benchmark indices ended in the red on Friday, extending their losing streak to a third consecutive week. The decline ...

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...